Readable research linked to original sources
Articles
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
14 articles
Newest firstIntroductionChanging trends in legal recreational cannabis markets necessitates the continuous monitoring of important market metrics such as price, potency, type, and availability of cannabis products which may influence consumer purchasing behavior. After initial legalization of recreational cannabis use in Canada in 2018 and expansion of the legal market in 2019, an increase in product types and decrease in pri…
Open article record in new tab ↗Given the increasing availability of high-potency Δ9-tetrahydrocannabinol (Δ9-THC) products, understanding potency-related effects of Δ9-THC on driving performance is an important public safety issue. This randomized, double-blind, placebo-controlled, within-subjects trial examined the effects of smoked cannabis with varying Δ9-THC concentrations on simulated driving. Adults aged 19–45 who regularly used cannabis…
BACKGROUND: It is well-established that cannabis can affect driving in the hours after cannabis use, but the exact duration of these effects, and relationship with delta-9-tetrahydrocannabinol (THC) concentrations in blood and oral fluid, remains to be determined. METHODS: Frequent (≥ 4 times a week) users of smoked cannabis drove a simulator the morning after (12-15 hours) last use of smoked cannabis; a control g…
Open article record in new tab ↗Objectives To examine next-day cognitive performance and subjective drug effects after smoking cannabis and to assess associations between performance and cannabinoid concentrations in blood and oral fluid. Methods In this observational study, healthy adults who regularly used cannabis (mean age 30 years; n = 65) smoked a legally purchased pre-rolled "joint" at night and were tested the next day, 12-15 h later. He…
Introduction Cannabis use and cannabis use disorder (CUD) are more prevalent among men and boys than among women and girls. However, this sex/gender gap has been narrowing in recent decades, likely due to an increase in cannabis use among women and girls, who have been historically under-represented in cannabis research. The lack of sex- and gender-based approaches within cannabis research has been highlighted in…
Open article record in new tab ↗IntroductionCannabis use and cannabis use disorder (CUD) are more prevalent among men and boys than among women and girls. However, this sex/gender gap has been narrowing in recent decades, likely due to an increase in cannabis use among women and girls, who have been historically under-represented in cannabis research. The lack of sex- and gender-based approaches within cannabis research has been highlighted in p…
Open article record in new tab ↗Legalization of cannabis use for non-medical (recreational) purposes is changing the global cannabis landscape. As attitudes toward cannabis use become more positive and prevalence of use increases in complex ways, concerns emerge about the potential for increased cannabis-attributable harms. Understanding the who, why, and when of this likely increase in cannabis-attributable harms is thus an important public hea…
Open article record in new tab ↗Background: There is a growing liberalization of cannabis-based preparations for medical and recreational use. In multiple instances, anxiety and depression are cited as either a primary or a secondary reason for the use of cannabinoids. Aim: The purpose of this review is to explore the association between depression or anxiety and the dysregulation of the endogenous endocannabinoid system (ECS), as well as the us…
Open article record in new tab ↗Genetic influences on acute responses to psychoactive drugs may contribute to individual variability in addiction risk. ABCB1 is a human gene that encodes P-glycoprotein, an ATP-dependent efflux pump that may influence the pharmacokinetics of delta-9-tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. Using data from 48 young adults (aged 19-25 years) reporting 1-4 days of cannabis use per…
Open article record in new tab ↗Cannabinoid co-administration may enable reduced opioid doses for analgesia. This updated systematic review on the opioid-sparing effects of cannabinoids considered preclinical and clinical studies where the outcome was analgesia or opioid dose requirements. We searched Scopus, Cochrane Central Registry of Controlled Trials, Medline, and Embase (2016 onwards). Ninety-two studies met the search criteria including 1…
Cannabidiol (CBD) is a non-intoxicating cannabinoid compound with diverse molecular targets and potential therapeutic effects, including effects relevant to the treatment of psychiatric disorders. In this scoping review, we sought to determine the extent to which sex and gender have been considered as potential moderators of the neuropsychiatric effects and pharmacokinetics of CBD. In this case, 300 articles were…
Open article record in new tab ↗Cannabis legalization for non-medical purposes (subsequently referred to as "cannabis legalization" or "legalization") took place in Canada in October 2018. One of the federal government's stated goals with cannabis legalization was to protect Canadian youth from cannabis-related harms. The main objective of this narrative review is to describe the impact of cannabis legalization on Canadian youth. To that end, we…
Open article record in new tab ↗As many jurisdictions consider relaxing cannabis legislation and usage is increasing in North America and other parts of the world, there is a need to explore the possible genetic differences underlying the subjective effects of cannabis. This pilot study investigated specific genetic variations within the cannabinoid receptor 1 (CNR1) gene for association with the subjective effects of smoked cannabis. Data were…
Legalization and commercial sale of non-medical cannabis has led to increasing diversity and potency of cannabis products. Some of the American states that were the first to legalize have seen rises in acute harms associated with cannabis use, e.g. Colorado has seen increases in emergency department visits for cannabis-related acute psychological distress and severe vomiting (hyperemesis), as well as a number of h…
Open article record in new tab ↗